Summary
Natural killer-like T lymphocytes termed cytokine-induced killer (CIK) cells have been shown to eradicate established tumours in a severe combined immune deficient (SCID) mouse/human lymphoma model. Recently, we demonstrated that CIK cells transfected with cytokine genes possess an improved proliferation rate and a significantly higher cytotoxic activity as compared to non-transfected cells. Here, in a phase I clinical protocol, autologous CIK cells were generated from peripheral blood obtained by leukapheresis in patients with metastatic renal cell carcinoma, colorectal carcinoma and lymphoma. CIK cells were transfected with a plasmid containing the interleukin-2 (IL-2) gene via electroporation. Transfected cells generated IL-2 in the range of 330–1800 pg 10–6 cells 24 h–1 with a mean of 836 pg 10–6 cells 24 h–1. Ten patients received 1–5 intravenous infusions of IL-2-transfected CIK cells; five infusions with transfected CIK cells were given. In addition, the same patients received five infusions with untransfected CIK cells for control reasons. In three patients, WHO grade 2 fever was observed. Based on polymerase chain reaction of peripheral blood transfected cells could be detected for up to 2 weeks after infusion. There was a significant increase in serum levels of interferon gamma (IFN-γ), granulocyte–macrophage colony-stimulating factor (GM-CSF) and transforming growth factor beta (TGF-β) during treatment. Interestingly, there was also an increase in CD3+ lymphocytes in the blood of patients during therapy. In accordance, a partial increase in cytotoxic activity in peripheral blood lymphocytes (PBLs) was documented when patient samples before and after therapy were compared. Concerning clinical outcome, six patients remained in progressive disease, three patients showed no change by treatment, and one patient with lymphoma developed a complete response. In conclusion, we were able to demonstrate that CIK cells transfected with the IL-2 gene can be administered without major side-effects and are promising for future therapeutic trials.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Buschle, M, Cotten, M, Kirlappos, H, Mechtler, K, Schaffner, G, Zauner, W, Birnstiel, ML & Wagner, E (1995). Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. Human Gene Ther 6: 753–761.
Csipai, M, Lefterova, P, Niemitz, S, Johnston, V, Scheffold, C, Huhn, D & Schmidt-Wolf, IGH (1996). Effects of interleukin-7 on proliferation of tumour cells. Cancer Res Ther Control 5: 11–16.
Ebert, O, Finke, S, Salahi, A, Herrmann, M, Trojaneck, B, Lefterova, P, Wagner, E, Kircheis, R, Neubauer, A, Huhn, D, Schriever, F, Wittig, B & Schmidt-Wolf, IGH (1997). Lymphocyte apoptosis: induction by gene transfer techniques. Gene Ther 4: 296–302.
Finke, S, Trojaneck, B, Lefterova, P, Csipai, M, Wagner, E, Kircheis, R, Neubauer, A, Huhn, D, Wittig, B & Schmidt-Wolf, IGH (1998). Increase of proliferation rate and enhancement of antitumour cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther 5: 31–39.
Grimm, EA, Mazumder, A, Zhang, HZ & Rosenberg, SA (1982). Lymphokine activated killer cell phenomenon: lysis of natural killer resistant fresh solid tumour cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841.
Hickman, CJ, Crim, JA, Mostowski, HS & Siegel, JP (1990). Regulation of human cytotoxic T-lymphocyte development by IL-7. J Immunol 145: 2415–2420.
Hwu, P, Yanelli, J, Kriegler, M, Anderson, WF, Perez, C, Chiang, Y, Schwarz, S, Cowherd, R, Delgado, C, Mule, J & Rosenberg, SA (1993). Functional and molecular characterization of tumour-infiltrating lymphocytes transduced with tumour necrosis factor alpha cDNA for the gene therapy of cancer in humans. J Immunol 150: 4104–4115.
Lotze, MT, Grimm, EA, Mazumder, A, Strausser, JL & Rosenberg, SA (1981). Lysis of fresh and cultured autologous tumour by human lymphocytes cultured in T cell growth factor. Cancer Res 41: 4420–4425.
Lu, PH & Negrin, RS (1994). A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumour activity in SCID mice. J Immunol 153: 1687–1696.
Lynch, DH & Miller, RE (1990). Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 145: 1983–1990.
Margolin, KA, Negrin, RS, Wong, KK, Chatterjee, S, Wright, C & Forman, SJ (1997). Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 157: 231–240.
Markowitz, SD & Roberts, AB (1996). Tumour suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 7: 93–102.
Mehta, BA, Schmidt-Wolf, IGH, Weissman, IL & Negrin, RS (1995). Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 86: 3493–3499.
Ramp, U, Jaquet, K, Reinecke, P, Nitsch, T, Gabbert, HE & Gerharz, CD (1997). Aquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 76: 739–749.
Riedl, E, Strobl, H, Majdic, O & Knapp, W (1997). TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J Immunol 158: 1591–1597.
Rosenberg, SA, Spiess, P & Lafreniere, R (1986). A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 1318–1321.
Rosenberg, SA, Aebersold, P & Cornetta, K (1990). Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570–578.
Schmidt-Wolf, GD & Schmidt-Wolf, IGH (1996). Cancer and gene therapy. Ann Hematol 73: 207–218.
Schmidt-Wolf, IGH, Negrin, RS, Kiem, HP, Blume, KG & Weissmann, IL (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139–149.
Schmidt-Wolf, IGH, Lefterova, P, Johnston, V, Huhn, D, Blume, KG & Weissmann, IL (1994a). Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 87: 453–458.
Schmidt-Wolf, IGH, Neubauer, A, Finke, S, Csipai, M, Wittig, B & Huhn, D (1994b). Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. Human Gene Ther 5: 1161–1168.
Schmidt-Wolf, GD, Negrin, RS & Schmidt-Wolf, IGH (1997). Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74: 51–56.
Welch, PA, Namen, AE, Goodwin, RG, Armitage, R & Cooper, MD (1989). Human IL-7: a novel T-cell growth factor. J Immunol 143: 3562–3567.
World Health Organization, (1979). WHO Handbook for Reporting Results of Cancer Treatment, WHO: Geneva.
Wright, JA & Huang, A (1996). Growth factors in mechanisms of malignancy: roles for TGF-beta and FGF. Histol Histopathol 11: 521–536.
Zoll, B, Lefterova, P, Finke, S, Trojaneck, B, Ebert, O, Micka, B, Roigk, K, Fehlinger, M, Schmidt-Wolf, GD, Huhn, D & Schmidt-Wolf, IGH (1998). Generation of cytokine-induced killer (CIK) cells using exogenous interleukin-2 (IL-2), -7 (IL-7) or -12 (IL-12). Cancer Immunol Immunother 47: 221–226.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Schmidt-Wolf, I., Finke, S., Trojaneck, B. et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81, 1009–1016 (1999). https://doi.org/10.1038/sj.bjc.6690800
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690800
Keywords
This article is cited by
-
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy
Cancer Immunology, Immunotherapy (2024)
-
Study on the antitumor effects of autologous and allogeneic CIK cells in patients with breast cancer*
Oncology and Translational Medicine (2021)
-
All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion
Scientific Reports (2017)
-
Cancer Immunotherapy with Cytokine-Induced Killer Cells
Targeted Oncology (2017)
-
Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study
Tumor Biology (2016)